van der Kleij, Maud B. A. http://orcid.org/0009-0008-8492-8039
Guchelaar, Niels A. D. http://orcid.org/0000-0001-8080-9093
Mathijssen, Ron H. J. http://orcid.org/0000-0001-5667-5697
Versluis, Jurjen http://orcid.org/0000-0003-2372-1663
Huitema, Alwin D. R. http://orcid.org/0000-0003-1939-4639
Koolen, Stijn L. W. http://orcid.org/0000-0002-0973-7530
Steeghs, Neeltje http://orcid.org/0000-0003-2989-2279
Article History
Accepted: 24 July 2023
First Online: 16 August 2023
Declarations
:
: No external funding was used in the preparation of this article.
: RHJM reported funding for investigator-initiated research from: Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche, Sanofi & Servier. All outside the submitted work, and payment to the institute. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, Luszana. N Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute. MvdK, NG, JV, AH and SK have declared no conflicts of interest.
: Not applicable.
: Not applicable.
: All authors consent to publication of this article.
: Not applicable because this is a review article.
: Not applicable.
: MvdK and NG performed the literature review and wrote the first draft. All authors were involved in the critical revision of the data, and the final manuscript.